1. Background {#sec1}
=============

In December 2019, the first case of unknown origin pneumonia was identified in Wuhan, the capital city of Hubei Province. By January 7, 2020, Chinese scientists had isolated a novel virus belongs to coronaviruses family and classified it as a type of RNA virus \[[@B1]\].

Although the outbreak has been started from a primary zoonotic virus transmission in a large seafood market (Huanan Seafood Market), person-to-person transmission of the virus started a pandemic involving 197 countries \[[@B2], [@B3]\].

The clinical outcomes of SARS-CoV-2 infection are various, including asymptomatic infection, mild upper respiratory tract illness, severe viral pneumonia, and even death. Patients are presented with various clinical manifestations such as fever, dyspnea, and cough \[[@B4]\].

Initially, some studies have observed particular imaging patterns on chest radiography and computed tomography in COVID-19 patients \[[@B5]\]. As our knowledge increased, recent studies claimed that the sensitivity of CT scan is higher compared to rRT-PCR in the diagnosis of COVID-19 \[[@B6]\].

Laboratory findings are essential in order to evaluate patients\' complications and triaging them \[[@B7]\]. Complete blood count as an easy and affordable test detects disorders such as leukopenia, anemia, and thrombocytopenia that are contributed to patients\' prognosis \[[@B8]\]. In response to inflammation induced by COVID-19, acute-phase reactants may increase or decrease \[[@B9]\]. These factors may contribute to the patients\' outcomes. This meta-analysis is aimed at measuring the most common clinical, laboratory, and imaging findings among COVID-19 patients.

2. Methods {#sec2}
==========

2.1. Protocol {#sec2.1}
-------------

In this study, we used a protocol based on the transparent reporting of systematic reviews and meta-analysis (PRISMA) (Figures [1](#fig1){ref-type="fig"}[](#fig2){ref-type="fig"}--[3](#fig3){ref-type="fig"}).

2.2. Eligibility Criteria {#sec2.2}
-------------------------

In this study, all included patients were confirmed using real-time reverse transcriptase-polymerase chain reaction (rRT-PCR). All searched articles were cross-sectional studies, reporting descriptive data, and no language restrictions were conducted. All articles published before drafting the manuscript have been included. Review articles, opinion articles, and letters not presenting original data were excluded from the analysis.

2.3. Information Sources and Search Strategy {#sec2.3}
--------------------------------------------

Three systematic searches were performed using Medline/PubMed, Scopus, and Web of Science. Systematic search was conducted prior to March 25, 2020, and three independent researchers evaluated all papers. The search was conducted based on the following keywords, and all studies were divided in three groups: (1) For clinical characteristics group: ("clinical manifestation" AND COVID-19) or ("clinical manifestation" AND 2019-nCoV) or ("clinical manifestation" AND COVID) or ("clinical manifestation" AND Corona) or ("clinical characteristics" AND COVID-19) or ("clinical characteristics" AND 2019-nCoV) or ("clinical characteristics" AND COVID) or ("clinical characteristics" AND corona). (2) For laboratory findings group: (liver AND COVID-19) or (liver AND 2019-nCoV) or (liver AND COVID) or (liver AND Corona) or ("blood gas" AND COVID-19) or ("blood gas" AND 2019-nCoV) or ("blood gas" AND COVID) or ("blood gas" AND corona). (3) For imaging studies group: (COVID-19 AND radiography) or (2019-nCoV AND radiography) or (Corona AND radiography) or (COVID AND radiography) or (COVID-19 AND radiographic) or (2019-nCoV AND radiographic) or (Corona AND radiographic) or (COVID AND radiographic) or (COVID-19 AND CT) or (2019-nCoV AND CT) or (Corona AND CT) or (COVID AND CT) or (COVID-19 AND "computed tomography") or (2019-nCoV AND "computed tomography") or (Corona AND "computed tomography") or (COVID AND "computed tomography") or (CBC AND corona) or (CBC AND COVID) or (CBC AND COVID-19) or (CBC AND 2019-nCoV).

2.4. Study Selection {#sec2.4}
--------------------

In the initial search, we assessed the title and abstract, followed by a full-text evaluation based on previously described inclusion and exclusion criteria. When two articles reported one patient\'s characteristics, we merged all reported data and assumed as a single individual. Descriptive studies reporting clinical symptoms, laboratory, and radiological findings were used to perform a meta-analysis. The characteristics of the included studies are shown in [Table 1](#tab1){ref-type="table"}. The modified appraisal tool for cross-sectional studies (AXIS) was used to determine the methodological quality of the research designs of the included studies ([Table 2](#tab2){ref-type="table"}). AXIS is used to assess research papers systematically and to judge the reliability of the study being presented in the paper. It also helps in assessing the worth and relevance of the study. Studies with total scores of ten or less were excluded.

2.5. Data Collection Process and Data Items {#sec2.5}
-------------------------------------------

Three independent researchers filled data extraction forms containing study type, journal, publication date, sample size, age, gender, clinical characteristics, laboratory, and radiological findings. Conflicts were resolved by another researcher.

2.6. Assessment of Methodological Quality and Risk of Bias {#sec2.6}
----------------------------------------------------------

Publication bias was assessed with a funnel plot for the standard error and considering that the interpretation of the plot is subjective (Figures [4](#fig4){ref-type="fig"}[](#fig5){ref-type="fig"}--[6](#fig6){ref-type="fig"}). Also, bias was quantified by using the Egger regression test.

Sensitivity analysis and adjusting for risk bias were performed by the attractive test (trim and fill method). We initially identified and trimmed the asymmetric (missing) studies, followed by estimating the unbiased summary effect. Sensitivity analysis was also performed using the "Remove-One" analysis by running the analysis with each of the studies removed. The result of the impact of each study on the pooled estimate is shown in the forest plot ([Figure 7](#fig7){ref-type="fig"}).

The percentage of total variation across studies (heterogeneity) was measured by the inconsistency index tool (*I* squared). The *I* squared index measured for each of the clinical characteristics, imaging studies, and laboratory findings groups. *I* squared index value in the ranges of \<25%, 25--50%, 50--75%, and \>75% was interpreted as low, moderate, high, and very high heterogeneity, respectively \[[@B10]\].

We conducted a random-effects analysis because it was assumed that some of the included studies did not share a common effect size (heterogeneity). Findings in each group are summarized as forest plots in Figures [8](#fig8){ref-type="fig"}[](#fig9){ref-type="fig"}--[10](#fig10){ref-type="fig"}.

2.7. Statistical Approach {#sec2.7}
-------------------------

Effect size pooled estimate for imaging and clinical data was measured based on event rate, logit event rate, and standard error.

Considering that the computational index of laboratory data was median in order to meta-analyze them in CMA v.2. software, we use the following formula:

Estimating the mean and variance from the median: $$\begin{matrix}
{S^{2} \approx \frac{1}{12}\left( {\frac{\left( {a - 2m + b} \right)^{2}}{4} + \left( {b - a} \right)^{2}} \right),} \\
{\overline{x} \approx \frac{a + 2m + b}{4},} \\
\end{matrix}$$where *m* is the median, *a* is the smallest value (minimum), *b* is the largest value (maximum), and *n* is the size of the sample \[[@B11]\].

The meta-analysis was performed using STATA, the software OpenMeta\[Analyst\], and Comprehensive Meta-Analysis Software (CMA) ve.2. Pooled estimate and their 95% confidence intervals (95% CIs) were used to summarize the weighted effect size for each study grouping variable.

3. Results {#sec3}
==========

3.1. Study Selection and Characteristics {#sec3.1}
----------------------------------------

Two hundred seven articles were included based on a search strategy, which are previously described ([Table 1](#tab1){ref-type="table"}). The full text of 65 articles was evaluated after the title and abstract assessment. Twenty-four articles were excluded due to inadequate data. Finally, the meta-analysis was performed on 30 articles (three different subjects). The article\'s data summary is reported in [Table 2](#tab2){ref-type="table"}. Also, demographic characteristics and comorbidities of patients participated in the included studies are demonstrated in [Table 3](#tab3){ref-type="table"}.

In this study, we evaluate 30 articles. All papers were from China, and 3420 individual\'s data were evaluated. All studies were cross-sectional, and 27 variables were included.

3.2. Heterogeneity {#sec3.2}
------------------

Evaluating the heterogeneity of the studies indicated that in the clinical characteristics and imaging studies groups, the combined effect of the *I* squared index is high (68.43, 68.53). While the laboratory findings groups combined effect of the *I* squared index is considered low (6.12). *I* squared index for each of the outcomes is shown in Tables [4](#tab4){ref-type="table"}[](#tab5){ref-type="table"}[](#tab6){ref-type="table"}--[7](#tab7){ref-type="table"}.

3.3. Publication Bias and Sensitivity Analysis {#sec3.3}
----------------------------------------------

The Funnel plot for clinical characteristics group studies is almost symmetric confirmed by the Egger regression test (intercept = −0.28, *P* value = 0.20). By using the random-effects model, the summary estimate and 95% confidence interval for the combined studies is 0.25 (0.22, 0.29). These findings indicated no publication bias in the clinical characteristics group ([Figure 4](#fig4){ref-type="fig"}).

The funnel plots in the imaging studies group and findings studies seem asymmetric and skewed (Figures [5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}). Also, the Egger regression test has indicated an intercept of 1.55, and *P* value of 0.01 for the laboratory findings group and an intercept of 0.94 and *P* value of 0.04 for the imaging studies group.

In the laboratory findings group, using the random-effects model, the point estimate and 95% confidence interval for the combined studies is 3.01 (2.22, 3.80). Using trim and fill (four trimmed studies), the imputed summary estimate is 3.30 (2.30, 3.38) ([Figure 5](#fig5){ref-type="fig"}).

In the imaging studies group, the summary estimate and 95% confidence interval for the combined studies is 0.51 (0.48, 0.54). Using trim and fill, the imputed (four trimmed studies) summary estimate is 0.50 (0.47, 0.53) ([Figure 6](#fig6){ref-type="fig"}).

In conclusion, the finding of trim and fill analysis has indicated only minimal changes, which do not seem to be a threat to the validity of the effect size estimates.

Sensitivity analysis by using the "Remove-One" analysis did not show any change in the combined effect of the clinical characteristics and imaging studies groups after removing any of the studies. However, in the laboratory findings group, removing only one of the studies (Fan et al.) changed the combined effect significantly ([Figure 7](#fig7){ref-type="fig"}). The combined effect before and after removing Fan et al. study is presented in Tables [5](#tab5){ref-type="table"} and [6](#tab6){ref-type="table"}.

3.4. Clinical Characteristics Group {#sec3.4}
-----------------------------------

According to clinical manifestations, fever (84.3%, 95% CI 78.6-88.7), cough (60.1%, 95% CI 53.5-66.4), and fatigue (39.4%, 95% CI 29.1-50.8) are the most prevalent clinical symptoms among patients ([Table 4](#tab4){ref-type="table"}) ([Figure 8](#fig8){ref-type="fig"}).

3.5. Laboratory Findings Group {#sec3.5}
------------------------------

Laboratory studies show increased level in following tests: CRP (10.78 mg/l, 95% CI 6.44-15.11) with the normal range of 0-3.0 mg/l, D-dimer (567.89 ng/ml, 95% CI 348.15-787.62) with the normal range of 0-500 ng/ml, LDH (258.56 U/l, 95% CI 206.84-310.29) with the normal range of 135-250 U/l, and procalcitonin (0.17 ng/ml, 95% CI 0.01-0.32) which is normally less than 0.05 ng/ml in a healthy individual.

Also, the level of some laboratory factors is lower than normal, such as lymphocyte (1.00∗10^9^/l, 95% CI 0.73-1.26) and albumin (38.61 g/l, 95% CI 35.75-41.48) concerning the normal range of 1‐4∗10^9^/l and 40-55 g/l, respectively (Tables [5](#tab5){ref-type="table"} and [6](#tab6){ref-type="table"}) ([Figure 9](#fig9){ref-type="fig"}).

3.6. Imaging Studies Group {#sec3.6}
--------------------------

Among all patients infected by SARS-CoV-2 (confirmed by RT-PCR), 85% had abnormalities in CT scans. In most of them, the bilateral pneumonia was dominant (79.4%, 95% CI 66.9-88.1). Ground-glass opacification (GGO) (69.8%, 95% CI 60.3-77.9), peripheral distribution (66.8%, 95% CI 50.0-80.2), and consolidation (37.8%, 95% CI 26.4-50.8) in those with CT scan results are presented ([Table 7](#tab7){ref-type="table"}) ([Figure 10](#fig10){ref-type="fig"}).

4. Discussion {#sec4}
=============

From December 2019, more than 500,000 cases of new unknown origin pneumonia have been confirmed all over the world \[[@B12]\]. It was primarily known as 2019-nCov; then, WHO decided to name this novel coronavirus "SARS-CoV-2" \[[@B13]\]. COVID-19 is a severe condition that is compromising the health condition of people in all countries worldwide \[[@B14]\]. Identifying the various characteristics of this infection is vital for controlling the outbreak in different countries \[[@B15]\]. Clinical, laboratory, and imaging findings are essential to evaluate the different aspects of infection \[[@B16]\]. Different outcomes of COVID-19 (from an asymptomatic infection to death) and contagiousness of this virus, even in its incubation period \[[@B17]\], emphasize why discovering different characteristics are crucial in controlling this pandemic.

In this systematic review and meta-analysis, we describe the most common clinical data on COVID-19 confirmed cases that were published during the first months of the outbreak. We analyzed 2422, rRT-PCR confirmed patients, for different clinical manifestations. Our findings are robust due to the pooled results after combining all the studies\' data.

As expected from initial studies in China, COVID-19 patients presented predominantly with cough and fever, as well as headache, diarrhea, and fatigue, among other clinical features \[[@B18]\]. This was consistently found in many of the included studies \[[@B19], [@B20]\]. Fever frequency is similar in other *β*-CoV-associated infections such as SARS and MERS, but studies showed that the cough frequency is higher in SARS and COVID-19 than MERS (\<50%) \[[@B21], [@B22]\]. In SARS and MERS, diarrhea is reported in about a quarter of patients, but our data shows that only 6 percent of COVID-19 patients present with diarrhea ([Table 4](#tab4){ref-type="table"}). Our data also suggest that about 11 percent of patients are presented with headache as a symptom. Unlike SARS, which is well characterized in the two-stage clinical course of the disease \[[@B23]\], COVID-19 still needs further definition to identify the disease process.

Studies on epidemiological features of COVID-19 showed that about 80 percent of patients are asymptomatic or are presented with mild manifestations \[[@B24], [@B25]\], but almost all of the patients included in our study had moderate-to-severe characteristics. It seems that fever and cough are the most common clinical features among moderate-to-severe patients ([Table 4](#tab4){ref-type="table"}).

Studies show different laboratory abnormalities in COVID-19 patients, such as hypoalbuminemia or elevated inflammatory markers \[[@B26]\]. However, our data suggest that C-reactive protein is the most elevated factor among infected cases (Tables [5](#tab5){ref-type="table"} and [6](#tab6){ref-type="table"}). D-dimer, LDH, and procalcitonin are also elevated in patients, which confirmed that measuring inflammatory markers are essential to investigate new cases \[[@B27]\]. Also, seven studies showed lymphopenia and albuminuria as other common laboratory findings. Data from new studies suggest lymphocytopenia or an increase in WBC as prognostic factors in COVID-19 patients. Studies on the SARS outbreak in 2003 indicate that lymphopenia, leukopenia, and thrombocytopenia, elevated levels of LDH, alanine transaminase (ALT), AST, and creatine-kinase are the most affected laboratory findings \[[@B28]\].

Nevertheless, not significantly seen in COVID-19, the novel corona virus can affect the liver and other organs \[[@B29]\]. AST and ALT are normal in most cases, but impaired liver function tests are associated with poor prognosis and higher mortality rates \[[@B30], [@B31]\]. Coagulation function tests (such as INR) are affected in the prognosis of this infection \[[@B32]\]. Lymphopenia in COVID-19 patients suggests that this virus might act on lymphocytes (mainly T cells), but some studies suggest that B cells are also affected \[[@B26], [@B33]\].

CT scan is one of the most useful methods to diagnose the respiratory tract diseases diagnosis. CT scan high sensitivity and availability makes it one of the most common tests for lung disease screening \[[@B34], [@B35]\]. In COVID-19 patients, different results could present in the early stages of infection \[[@B36], [@B37]\]; even some studies demonstrate that CT scan sensitivity is higher than rRT-PCR \[[@B6]\]. Our data shows that 92% of rRT-PCR confirmed cases had abnormal CT scan results, which suggest CT scan as a reliable method. As seen in [Table 7](#tab7){ref-type="table"}, CT scan meta-analysis outcomes are performed in random-effects analyses. Our meta-analysis on 15 studies showed that ground-glass opacification (GGO) and peripheral distribution are seen on 69.8% and 66.8% of patients, respectively. 79.4% of the patients had bilateral involvements, which is contributed to poor prognosis. CT scan is useful in monitoring the treatment, and it is crucial in classifying patients and identifying who should be treated with aggressive treatments \[[@B38]\]. Other findings such as consolidation or reverse halo or atoll sign are reported in some studies \[[@B39]\], which were not included in our analysis.

5. Limitations {#sec5}
==============

This review has several limitations. Few studies are available on COVID-19, and most of them are from China. Many countries such as Italy, the United States, and Iran reported several new COVID-19 patients, but data about clinical characteristics or laboratory findings are limited. By publishing more studies worldwide, researchers are going to get a more comprehensive understanding of COVID-19. Patients\' detailed information, especially in clinical outcomes, was unavailable in most studies at the time of analysis. In this study, we used random-effects model for analysis in all three groups. In comparison to the fixed model, random model findings have wider confidence intervals and less accurate results, although heterogeneity in included studies could not be considered in the fixed model.

6. Conclusion {#sec6}
=============

COVID-19 presents in the majority of cases with fever and cough. Laboratory findings such as elevated inflammatory markers can assist the diagnosis. Other laboratory indices, such as AST, ALT, or INR, are also affected in these patients. 92% of the RT-PCR confirmed that patients have abnormalities in CT scan most frequently bilateral involvement. Additional research with higher sample sizes is needed in order to describe the patients\' characteristics more precisely.
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###### 

Characteristics of the included studies.

  Row                        Author            Journal                                                        Type              Date     Country   Sample size   Reference
  -------------------------- ----------------- -------------------------------------------------------------- ----------------- -------- --------- ------------- ------------
  Imaging                                                                                                                                                        
  1                          Fang et al.       *Radiology*                                                    Cross-sectional   Feb 19   China     51            \[[@B6]\]
  2                          Zhao et al.       *American Journal of Roentgenology*                            Cross-sectional   Feb 18   China     101           \[[@B38]\]
  3                          Shi et al.        *The Lancet*                                                   Cross-sectional   Feb 24   China     81            \[[@B40]\]
  4                          Pan et al.        *European Radiology*                                           Cross-sectional   Feb 13   China     63            \[[@B41]\]
  5                          Xu et al.         *European Journal of Nuclear Medicine and Molecular Imaging*   Cross-sectional   Feb 28   China     90            \[[@B42]\]
  6                          Zhang et al.      *European Respiratory Journal*                                 Cross-sectional   Mar 25   China     17            \[[@B43]\]
  7                          Chen et al.       *The Lancet*                                                   Cross-sectional   Jan 30   China     99            \[[@B44]\]
  8                          Huang             *The Lancet*                                                   Cross-sectional   Feb 21   China     41            \[[@B18]\]
  9                          Wu et al.         *Clinical Infectious Diseases*                                 Cross-sectional   Feb 29   China     80            \[[@B19]\]
  10                         Guan et al.       *The New England Journal of Medicine*                          Cross-sectional   Feb 28   China     1099          \[[@B45]\]
  11                         Wang et al.       *Clinical Infectious Diseases*                                 Cross-sectional   Feb 29   China     138           \[[@B46]\]
  12                         Yang et al.       *Journal of Infection*                                         Cross-sectional   Feb 26   China     149           \[[@B47]\]
  13                         Xu et al.         *Journal of Infection*                                         Cross-sectional   Feb 25   China     50            \[[@B48]\]
  14                         Wu et al.         *Investigative Radiology*                                      Cross-sectional   Feb 29   China     80            \[[@B49]\]
  15                         Li et al.         *Investigative Radiology*                                      Cross-sectional   Feb 29   China     83            \[[@B50]\]
  16                         Xia et al.        *Pediatric Pulmonology*                                        Cross-sectional   Mar 05   China     20            \[[@B51]\]
  17                         Zhang et al.      *Allergy*                                                      Cross-sectional   Feb 19   China     140           \[[@B52]\]
  18                         Zhou et al.       *American Journal of Roentgenology*                            Cross-sectional   Feb 16   China     62            \[[@B53]\]
  19                         Wang et al.       *Journal of Zhejiang University*                               Cross-sectional   Feb 24   China     52            \[[@B54]\]
  20                         Yoon et al.       *Korean J Radiol*                                              Cross-sectional   Apr 21   China     9             \[[@B55]\]
  Laboratory                                                                                                                                                     
  21                         Qian et al.       *An International Journal of Medicine*                         Cross-sectional   Feb 21   China     91            \[[@B56]\]
  22                         Liu et al.        *medRxiv*                                                      Cross-sectional   Feb 21   China     109           \[[@B57]\]
  23                         Chen et al.       *medRxiv*                                                      Cross-sectional   Feb 14   China     21            \[[@B58]\]
  24                         Young et al.      *Jama*                                                         Cross-sectional   Feb 24   China     18            \[[@B59]\]
  25                         Fan et al.        *The Lancet*                                                   Cross-sectional   Mar 05   China     148           \[[@B30]\]
  26                         Wu et al.         *Clinical Infectious Diseases*                                 Cross-sectional   Feb 29   China     80            \[[@B19]\]
  27                         Guan et al.       *New England Journal of Medicine*                              Cross-sectional   Feb 28   China     1099          \[[@B45]\]
  Clinical characteristics                                                                                                                                       
  28                         Chen et al.       *The Lancet*                                                   Cross-sectional   Feb 21   China     99            \[[@B44]\]
  29                         Deng and Peng     *Journal Clinical Medicine*                                    Cross-sectional   Feb 14   China     41            \[[@B60]\]
  30                         Huang             *Clinical Gastroenterology and Hepatology*                     Cross-sectional   Feb 21   China     41            \[[@B18]\]
  31                         Guan et al.       *The New England Journal of Medicine*                          Cross-sectional   Feb 19   China     1099          \[[@B45]\]
  32                         Huang et al.      *Travel Medicine and Infectious Disease*                       Cross-sectional   Feb 24   China     34            \[[@B61]\]
  33                         Kui et al.        *Chinese Medical Journal*                                      Cross-sectional   Feb 07   China     137           \[[@B62]\]
  34                         Tian et al.       *Journal of Infection*                                         Cross-sectional   Feb 27   China     262           \[[@B63]\]
  35                         Wang et al.       *Jama*                                                         Cross-sectional   Feb 21   China     138           \[[@B46]\]
  36                         Wu et al.         *Clinical Infectious Diseases*                                 Cross-sectional   Feb 29   China     80            \[[@B19]\]
  37                         Xu et al.         *European Journal of Nuclear Medicine and Molecular Imaging*   Cross-sectional   Feb 28   China     90            \[[@B42]\]
  38                         Xiao-Wei et al.   *BMJ: British Medical Journal*                                 Cross-sectional   Feb 19   China     62            \[[@B64]\]
  39                         Xu et al.         *Journal of Infection*                                         Cross-sectional   Feb 25   China     50            \[[@B48]\]
  40                         Yang et al.       *Journal of Infection*                                         Cross-sectional   Feb 26   China     149           \[[@B47]\]
  41                         Zhang et al.      *Allergy*                                                      Cross-sectional   Feb 19   China     140           \[[@B52]\]

###### 

Appraisal tool for cross-sectional studies (AXIS) scores of included studies.

  Row   Author            Date     AXIS score   Reference                    
  ----- ----------------- -------- ------------ ----------- --- --- --- ---- ------------
  1     Fang et al.       Feb 19   1            6           4   2   2   15   \[[@B6]\]
  2     Zhao et al.       Feb 18   1            8           3   2   2   16   \[[@B38]\]
  3     Shi et al.        Feb 24   1            9           3   2   2   17   \[[@B40]\]
  4     Pan et al.        Feb 13   1            7           2   2   2   14   \[[@B41]\]
  5     Xu et al.         Feb 28   1            6           4   2   2   15   \[[@B42]\]
  6     Zhang et al.      Mar 25   1            7           2   2   2   14   \[[@B43]\]
  7     Chen et al.       Jan 30   1            8           5   2   2   18   \[[@B44]\]
  8     Huang             Feb 21   1            8           5   2   2   18   \[[@B18]\]
  9     Wu et al.         Feb 29   1            6           2   2   1   12   \[[@B19]\]
  10    Guan et al.       Feb 28   1            9           5   2   2   19   \[[@B45]\]
  11    Wang et al.       Feb 29   1            9           5   2   2   19   \[[@B46]\]
  12    Yang et al.       Feb 26   1            5           3   2   2   13   \[[@B47]\]
  13    Xu et al.         Feb 25   1            6           4   2   2   15   \[[@B48]\]
  14    Wu et al.         Feb 29   1            9           3   2   2   17   \[[@B49]\]
  15    Li et al.         Feb 29   1            8           5   2   2   18   \[[@B50]\]
  16    Xia et al.        Mar 05   1            5           2   2   2   12   \[[@B51]\]
  17    Zhang et al.      Feb 19   1            6           2   1   2   12   \[[@B52]\]
  18    Zhou et al.       Feb 16   1            5           4   2   2   14   \[[@B53]\]
  19    Wang et al.       Feb 24   1            7           3   2   2   15   \[[@B54]\]
  20    Yoon et al.       Apr 21   1            4           3   2   2   12   \[[@B55]\]
  21    Qian et al.       Feb 21   1            7           4   2   2   16   \[[@B56]\]
  22    Liu et al.                 1            6           4   2   2   15   \[[@B57]\]
  23    Chen et al.                1            5           2   2   2   12   \[[@B58]\]
  24    Young et al.      Feb 24   1            8           4   2   2   17   \[[@B59]\]
  25    Fan et al.        Mar 05   1            8           3   2   2   16   \[[@B30]\]
  29    Deng and Peng     Feb 14   1            5           5   2   2   15   \[[@B60]\]
  32    Huang et al.      Feb 24   1            5           3   2   2   13   \[[@B61]\]
  33    Kui et al.        Feb 07   1            5           3   2   2   13   \[[@B62]\]
  34    Tian et al.       Feb 27   1            5           3   2   2   13   \[[@B63]\]
  38    Xiao-Wei et al.   Feb 19   1            7           2   2   2   14   \[[@B64]\]

###### 

Demographical characteristics and comorbidities of patients in the included studies.

  Row   Author          Date     Sample size   Mean age (y. old)   Age range   Sex (male)   Diabetes   Hypertension   Cardiovascular disease   COPD   Malignancies   Digestive system disease
  ----- --------------- -------- ------------- ------------------- ----------- ------------ ---------- -------------- ------------------------ ------ -------------- --------------------------
  1     Fang et al.     Feb 19   51            45                  39-55       29           ---        ---            ---                      ---    ---            ---
  2     Zhao et al.     Feb 18   101           44/44               17-75       56           ---        ---            15/8                     4/9    ---            ---
  3     Shi et al.      Feb 24   81            49/5                39-61       42           12         15             10                       11     5              9
  4     Pan et al.      Feb 13   63            44/9                31-62       33           ---        ---            ---                      ---    ---            ---
  5     Xu et al.       Feb 28   90            50                  18-86       39           6          19             3                        1      2              2
  6     Zhang et al.    Mar 25   17            48/6                23-74       8            ---        11/7           5                        11     ---            11/7
  7     Chen et al.     Jan 30   99            55/5                21-82       67           ---        ---            40                       1      1              11
  8     Huang           Feb 21   41            49                  41-58       30           20         15             15                       2      2              2
  9     Wu et al.       Feb 29   80            46                  18-65       39           ---        ---            31/25                    1/25   1/25           3/75
  10    Guan et al.     Feb 28   1096          49                  35-58       637          7/4        15             3/9                      1/1    0/9            2/1
  11    Wang et al.     Feb 29   138           56                  42-68       75           10/1       31/2           14/5                     2/9    7/2            2/9
  12    Yang et al.     Feb 26   149           45/1                30-68       81           ---        ---            18/79                    0/67   1/34           5/37
  13    Xu et al.       Feb 25   50            43                  3-85        29           ---        ---            ---                      ---    ---            ---
  14    Wu et al.       Feb 29   80            44                  30-52       42           5          5              1                        4      ---            ---
  15    Li et al.       Feb 29   83            45/5                25-64       44           7/8        6              1/2                      6      ---            ---
  16    Xia et al.      Mar 05   20            1                   0-7         13           ---        ---            ---                      ---    ---            ---
  17    Zhang et al.    Feb 19   135           57                  25-87       71           12         30             12/1                     2/8    ---            10/7
  18    Zhou et al.     Feb 16   62            52/8                30-77       39           6          6              1                        ---    ---            ---
  19    Wang et al.     Feb 24   52            ---                 ---         ---          ---        ---            ---                      ---    ---            ---
  20    Yoon et al.     Apr 21   9             54                  ---         ---          ---        ---            ---                      ---    ---            ---
  21    Qian et al.     Feb 21   91            50                  36-57       37           8/79       16/48          3/3                      ---    ---            ---
  22    Liu et al.               109           55                  43-66       59           11         33             6/4                      3/7    ---            ---
  23    Chen et al.              21            56                  ---         17           14/3       23/8           ---                      ---    ---            ---
  24    Young et al.    Feb 24   18            47                  31-73       9            ---        ---            ---                      ---    ---            ---
  25    Fan et al.      Mar 05   148           50                  36-64       73           ---        ---            ---                      ---    ---            ---
  26    Xu et al.       Feb 19   62            41                  32-52       36           2          8              2                        2      ---            11
  27    Deng and Peng   Feb 14   41            55/5                25-89                    42/3       53/8           19/2                     19/2   ---            ---
  28    Huang et al.    Feb 24   34            56/24               26-88       14           11/8       23/5           17/6                     2/9    8/8            2/9
  29    Kui et al.      Feb 07   137           57                  20-83       61           9/5        10/2           7/3                      1/5    1/5            ---
  30    Tian et al.     Feb 27   262           47/5                1-94        127          ---        ---            ---                      ---    ---            ---

###### 

A meta-analysis of clinical characteristics group.

  Clinical group        Effect size and 95% confidence interval   Test of null (2-tail)   Heterogeneity                             
  --------------------- ----------------------------------------- ----------------------- --------------- ------- --------- ------- --------
  Cough                 14                                        0.601                   0.535           0.664   2.975     0.003   87.304
  Fever                 14                                        0.843                   0.786           0.887   8.650     0.000   87.006
  Headache              12                                        0.091                   0.070           0.118   -15.933   0.000   57.760
  Diarrhea              11                                        0.064                   0.043           0.095   -12.258   0.000   71.281
  Fatigue               11                                        0.394                   0.291           0.508   -1.827    0.068   94.073
  Dyspnea               8                                         0.171                   0.091           0.298   -4.290    0.000   92.769
  Expectoration         5                                         0.239                   0.164           0.334   -4.840    0.000   77.659
  Hemoptysis            5                                         0.023                   0.009           0.057   -7.652    0.000   70.741
  Shortness of breath   5                                         0.241                   0.151           0.361   -3.898    0.000   87.758
  Sore throat           5                                         0.130                   0.085           0.193   -7.866    0.000   78.329
  Muscle ache           4                                         0.114                   0.052           0.231   -4.749    0.000   83.406
  Nausea                2                                         0.109                   0.038           0.275   -3.633    0.000   81.783

###### 

Meta-analysis of laboratory findings before removing Fan et al. study.

  Group LAB test             Effect size and 95% confidence interval   Test of null (2-tail)   Heterogeneity                                                 
  -------------------------- ----------------------------------------- ----------------------- --------------- ---------- -------- -------- ------- -------- -------
  CRP (mg/l)                 7                                         10.78                   2.21            4.89       6.44     15.11    4.87    0.0000   30.63
  Lymphocytes (×10^9^/l)     7                                         1.00                    0.13            0.02       0.73     1.26     7.48    0.0000   45.87
  WBC (×10^9^/l)             7                                         4.87                    0.26            0.07       4.36     5.38     18.76   0.0000   0.00
  ALT (U/l)                  5                                         23.43                   2.84            8.07       17.86    29.00    8.25    0.0000   0.00
  AST (U/l)                  5                                         25.84                   2.47            6.08       21.01    30.68    10.48   0.0000   1.71
  Cr (*μ*mol/l)              5                                         69.90                   3.87            14.97      62.32    77.48    18.06   0.0000   0.00
  D-dimer (*μ*g/l)           5                                         567.89                  112.11          12568.89   348.15   787.62   5.07    0.0000   0.00
  Hemoglobin (g/l)           5                                         131.71                  3.37            11.38      125.10   138.32   39.05   0.0000   0.00
  LDH (U/l)                  5                                         258.56                  26.39           696.51     206.84   310.29   9.80    0.0000   11.06
  Neutrophils (×10^9^/l)     5                                         3.20                    0.31            0.09       2.59     3.80     10.38   0.0000   0.00
  Platelets (×10^9^/l)       5                                         166.39                  10.92           119.17     145.00   187.79   15.24   0.0000   0.00
  Procalcitonin (ng/ml)      5                                         0.17                    0.08            0.01       0.01     0.32     2.15    0.0312   68.47
  Creatine kinase (U/l)      4                                         110.18                  19.92           396.72     71.14    149.22   5.53    0.0000   0.00
  Total bilirubin (mmol/l)   4                                         8.36                    1.08            1.16       6.25     10.48    7.76    0.0000   0.00
  Albumin (g/l)              3                                         38.61                   1.46            2.14       35.75    41.48    26.41   0.0000   44.52
  BUN (mmol/l)               3                                         4.83                    0.55            0.30       3.75     5.91     8.77    0.0000   0.00
  ESR                        2                                         40.79                   24.93           621.75     -8.08    89.67    1.64    0.1018   91.15
  Fibrinogen (g/l)           2                                         3.21                    0.22            0.05       2.78     3.64     14.71   0.0000   0.00

###### 

Meta-analysis of laboratory findings after removing Fan et al. study.

  Laboratory findings group (one study removed)   Effect size and 95% confidence interval   Test of null (2-tail)   Heterogeneity                           
  ----------------------------------------------- ----------------------------------------- ----------------------- --------------- -------- ------- ------ -------
  CRP (mg/l)                                      6                                         9.13                    6.00            12.27    5.71    0.00   1.73
  Lymphocytes (×10^9^/l)                          6                                         0.99                    0.78            1.20     9.20    0.00   37.93
  WBC (×10^9^/l)                                  6                                         4.88                    4.31            5.45     16.75   0.00   0.00
  ALT (U/l)                                       5                                         23.43                   17.86           29.00    8.25    0.00   0.00
  AST (U/l)                                       5                                         25.84                   21.01           30.68    10.48   0.00   1.71
  Cr (*μ*mol/l)                                   5                                         69.90                   62.32           77.48    18.06   0.00   0.00
  D-dimer (*μ*g/l)                                5                                         567.89                  348.15          787.62   5.07    0.00   0.00
  Hemoglobin (g/l)                                5                                         131.71                  125.10          138.32   39.05   0.00   0.00
  LDH (U/l)                                       5                                         258.56                  206.84          310.29   9.80    0.00   11.06
  Neutrophils (×10^9^/l)                          5                                         3.20                    2.59            3.80     10.38   0.00   0.00
  Platelets (×10^9^/l)                            5                                         166.39                  145.00          187.79   15.24   0.00   0.00
  Procalcitonin (ng/ml)                           5                                         0.17                    0.01            0.32     2.15    0.03   68.47
  Creatine kinase (U/l)                           4                                         110.18                  71.14           149.22   5.53    0.00   0.00
  Total bilirubin (mmol/l)                        4                                         8.36                    6.25            10.48    7.76    0.00   0.00
  Albumin (g/l)                                   3                                         38.61                   35.75           41.48    26.41   0.00   44.52
  BUN (mmol/l)                                    3                                         4.83                    3.75            5.91     8.77    0.00   0.00
  Fibrinogen (g/l)                                2                                         3.21                    2.78            3.64     14.71   0.00   0.00

###### 

A meta-analysis of imaging study outcomes.

  CT group                                 Number of studies   Effect size and 95% confidence interval   Test of null (2-tail)   Heterogeneity                    
  ---------------------------------------- ------------------- ----------------------------------------- ----------------------- --------------- -------- ------- --------
  Total (CT+)                              20                  0.923                                     0.877                   0.953           9.290    0.000   81.398
  \(1\) Ground-glass opacification (GGO)   14                  0.698                                     0.603                   0.779           3.890    0.000   90.700
  \(4\) Bilateral involvement              11                  0.794                                     0.669                   0.881           4.081    0.000   93.032
  \(5\) Consolidation                      11                  0.378                                     0.264                   0.508           -1.845   0.065   90.564
  \(3\) Peripheral distribution            6                   0.668                                     0.500                   0.802           1.955    0.051   88.951
  \(10\) Unilateral involvement            5                   0.156                                     0.082                   0.278           -4.510   0.000   71.765
  (∗∗) Mixed opacity                       4                   0.328                                     0.121                   0.635           -1.106   0.269   97.487
  \(11\) Air bronchogram                   4                   0.426                                     0.225                   0.656           -0.618   0.537   87.500
  \(6\) Pleural effusion                   4                   0.066                                     0.036                   0.120           -7.950   0.000   14.830
  \(7\) Adjacent pleura thickening         4                   0.409                                     0.211                   0.641           -0.764   0.445   92.842
  \(12\) Fibrous stripes                   3                   0.229                                     0.056                   0.596           -1.486   0.137   93.828
  \(2\) Lower lung predominant             3                   0.624                                     0.467                   0.758           1.558    0.119   64.196
  \(8\) Interlobular septal thickening     3                   0.535                                     0.359                   0.703           0.379    0.705   85.123
  1 lobe affected                          2                   0.207                                     0.087                   0.417           -2.608   0.009   83.897
  2 lobes affected                         2                   0.061                                     0.032                   0.113           -7.927   0.000   0.000
  3 lobes affected                         2                   0.105                                     0.047                   0.220           -4.796   0.000   57.131
  4 lobes affected                         2                   0.099                                     0.060                   0.157           -8.135   0.000   0.000
  5 lobes affected                         2                   0.394                                     0.312                   0.483           -2.331   0.020   18.313
  \(9\) Cavitation                         2                   0.012                                     0.002                   0.082           -4.350   0.000   0.000
  Crazy-paving pattern                     2                   0.222                                     0.067                   0.530           -1.786   0.074   92.080
  Linear opacities                         2                   0.630                                     0.555                   0.699           3.372    0.001   0.000

[^1]: Academic Editor: Valeria Cavalcanti Rolla
